LX1001

Lexeo Therapeutics · Phase 1 active Biologic Quality 0/100

At a glance

Generic name	LX1001
Also known as	AAVrh.10hAPOE2
Sponsor	Lexeo Therapeutics
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (PHASE1, PHASE2)
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LX1001 CI brief — competitive landscape report
LX1001 updates RSS · CI watch RSS
Lexeo Therapeutics portfolio CI